Novo Nordisk shares rebound despite disappointing CagriSema trial results By Investing.com
Investing.com -- Novo Nordisk (CSE:) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. ...









